A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia

Exclusion Criteria

• •Women who are pregnant, plan to become pregnant in the next 4 months, or lactating females.
• •Unwilling to use stringent methods of contraception (including barrier method, as well as another acceptable method) throughout the course of the study.
• •History of cancer, except basal cell or squamous cell carcinoma of the skin.
• •History of genital herpes with outbreak within prior 12 months.
• •Have an active pelvic or non-HPV (Human papillomavirus) vaginal infection (e.g., that was detected by a positive urine screen for gonorrhea or chlamydial infection, bimanual exam consistent with pelvic inflammatory disease, positive bedside testing criteria for bacterial vaginosis, candida vaginitis or trichomonal vaginitis, etc).
• •Current or recent abnormal vaginal discharge and /or abnormal vaginal bleeding.
• •Had a therapeutic abortion or miscarriage less than 3 months prior.
• •Any clinically significant immune suppressing condition.
• •Participants with a significant acute condition or any other condition that in the opinion of the Investigator might interfere with the evaluation of the study objectives.
• •Women who, in the PI's judgment, would be harmed by the delay in undergoing definitive treatment as a result of study participation and the ABI-2280 Vaginal Tablet dosing schedule.
• •Vaccination (even 1 dose) with a prophylactic HPV vaccine (i.e., Gardasil®, Gardasil®-9 or Cervarix®) in the last 3 months.
• •Vaccination with a therapeutic HPV vaccine.